Ads
related to: monoclonal antibody treatment prostate cancer debate video today news- Sign Up For Updates
Rx For Advanced Prostate Cancer
Get Information & Updates
- Formulary Lookup Tool
View our Formulary Lookup
For a Prostate Cancer Treatment
- Coverage for Rx Treatment
Learn About Coverage
In Your Area
- Educational Brochures
Get Resources Now For
APC Treatment
- Sign Up For Updates
Search results
Results from the WOW.Com Content Network
Capromab is a mouse monoclonal antibody which recognizes a protein found on both prostate cancer cells and normal prostate tissue. It is linked to pendetide , a derivative of DTPA . [ 2 ] Pendetide acts as a chelating agent for the radionuclide indium-111 .
Abituzumab is a humanized IgG2 monoclonal antibody (mAb) targeted at CD51 (an integrin) currently in development by Merck KGaA Darmstadt, Germany in an attempt to prevent bone lesion metastases in castration-resistant prostate cancer. [1] [2]
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Federal supply of the one monoclonal antibody treatment that has proven effective is now "limited," with more doses expected in January, a Health and Human Services spokesperson said.
It is a recombinant humanized monoclonal antibody of the immunoglobulin IgG1 subclass against the interleukin-6 receptor (IL-6R). [18] Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer.
Anti-cancer monoclonal antibodies can be targeted against malignant cells by several mechanisms. Ramucirumab is a recombinant human monoclonal antibody and is used in the treatment of advanced malignancies. [18] In childhood lymphoma, phase I and II studies have found a positive effect of using antibody therapy. [19]
Durvalumab, [8] sold under the brand name Imfinzi, is an anti-cancer medication used for treatment of various types of cancer. [6] It was developed by Medimmune / AstraZeneca . [ 9 ] It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 ( PD-L1 ).
Panitumumab was approved by the European Medicines Agency (EMEA) in 2007, and by Health Canada in 2008, for "the treatment of refractory EGFR-expressing metastatic colorectal cancer in patients with non-mutated (wild-type) KRAS". Panitumumab was the first monoclonal antibody to demonstrate the use of KRAS as a predictive biomarker.
Ads
related to: monoclonal antibody treatment prostate cancer debate video today news